Simple blood test after heparin could spot High-Risk pregnancies
NCT ID NCT02855047
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 513 women with antiphospholipid syndrome starting a new pregnancy. Researchers measured two blood markers (PGF and sFlt1) before and after the first low-molecular-weight heparin injections. The goal was to see if changes in these markers could predict serious pregnancy complications like preeclampsia, placental abruption, or poor fetal growth. The study is completed and aims to improve monitoring, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-molecular-weight heparin
What this could lead to
If successful, this could help doctors predict which pregnancies are at risk for complications like preeclampsia or fetal growth restriction.
What could go wrong
This is an observational study, not a treatment trial. It only measures markers and does not test a new therapy, so it may not directly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémea
Nîmes, 30029, France